Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Prescription, Nonprescription and Orphan Drugs01:02

Prescription, Nonprescription and Orphan Drugs

Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Drug Regulation01:25

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bevifibatide: First Approval.

Drugs·2026
Same author

Remibrutinib: First Approval.

Drugs·2026
Same author

Correction: Ifupinostat: First Approval.

Drugs·2026
Same author

Ifupinostat: First Approval.

Drugs·2025
Same author

Fosrolapitant/Palonosetron: First Approval.

Drugs·2025
Same author

Nipocalimab: First Approval.

Drugs·2025
Same journal

Desvenlafaxine as a Potential First-Line Treatment for Major Depressive Disorder: A Comprehensive Review and Consensus-Based Clinical Perspective on Efficacy, Safety and Patient Selection Profiles.

Clinical drug investigation·2026
Same journal

Effectiveness of the Approved Nirmatrelvir/Ritonavir and Molnupiravir Regimens for Treatment of Mild/Moderate Laboratory-Confirmed SARS-CoV-2 Infection in Patients Aged 18-64 Years in Hong Kong: A Population-Based Cohort Study.

Clinical drug investigation·2026
Same journal

Assessing the Adverse Events of Roflumilast and Tapinarof Use in Pediatric and Young Adult Patients with Atopic Dermatitis: A Systematic Review.

Clinical drug investigation·2026
Same journal

Repurposing Antipsychotics in Cancer Therapy: Modulation of Autophagy Mechanisms.

Clinical drug investigation·2026
Same journal

Efficacy, Safety, Quality of Life, and Adherence of Dupilumab in Pediatric Atopic Dermatitis: A Systematic Review.

Clinical drug investigation·2026
Same journal

Optimizing Amiodarone Maintenance Dose to Minimize N-Desethylamiodarone Accumulation and Pulmonary Toxicity: Insights from Machine Learning and Pharmacokinetic Simulation.

Clinical drug investigation·2026
See all related articles

Related Experiment Video

Updated: Jul 2, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Deuruxolitinib: New Approval.

Simon Fung1

  • 1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. cdi@adis.com.

Clinical Drug Investigation
|July 1, 2026
PubMed
Summary
This summary is machine-generated.

Deuruxolitinib, a new alopecia areata treatment, has gained FDA and UK approval. This Janus kinase (JAK) inhibitor offers a novel therapeutic option for severe cases in adults.

More Related Videos

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

Related Experiment Videos

Last Updated: Jul 2, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

Area of Science:

  • Dermatology
  • Pharmacology
  • Immunology

Background:

  • Alopecia areata is an autoimmune condition causing hair loss.
  • Current treatments have limitations, necessitating novel therapeutic approaches.
  • Janus kinase (JAK) inhibitors show promise in modulating immune responses implicated in alopecia areata.

Purpose of the Study:

  • To summarize the development milestones of deuruxolitinib.
  • To highlight the regulatory approvals for deuruxolitinib in severe alopecia areata.
  • To provide an overview of deuruxolitinib as a treatment for alopecia areata.

Main Methods:

  • Review of clinical development data for deuruxolitinib.
  • Analysis of regulatory submission and approval timelines.
  • Pharmacological profiling of deuruxolitinib as a JAK inhibitor.

Main Results:

  • Deuruxolitinib, a deuterated JAK1/2 inhibitor, has been developed for alopecia areata.
  • The drug received US FDA approval in July 2024 for severe alopecia areata in adults.
  • UK approval was granted in March 2026 for the same indication.

Conclusions:

  • Deuruxolitinib represents a significant advancement in alopecia areata treatment.
  • The drug's approval marks a milestone in managing severe forms of the condition.
  • Further research may explore deuruxolitinib's efficacy in broader patient populations.